Geron Corp. (GERN) Given Consensus Recommendation of “Buy” by Brokerages
Geron Corp. (NASDAQ:GERN) has received a consensus rating of “Buy” from the seven analysts that are covering the firm. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $5.00.
Several equities analysts have recently weighed in on the company. FBR & Co decreased their price objective on Geron Corp. from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 13th. BTIG Research assumed coverage on Geron Corp. in a report on Friday, August 19th. They issued a “neutral” rating for the company. Piper Jaffray Cos. restated an “overweight” rating and issued a $5.00 price objective (down previously from $10.00) on shares of Geron Corp. in a report on Tuesday, September 13th. Finally, Zacks Investment Research upgraded Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 price objective for the company in a report on Friday, August 5th.
A number of institutional investors have recently bought and sold shares of GERN. Bellevue Group AG acquired a new position in Geron Corp. during the first quarter worth approximately $131,000. A.R.T. Advisors LLC boosted its position in Geron Corp. by 59.0% in the first quarter. A.R.T. Advisors LLC now owns 661,334 shares of the biopharmaceutical company’s stock worth $1,931,000 after buying an additional 245,500 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Geron Corp. during the first quarter worth approximately $1,324,000. Bank of Montreal Can acquired a new position in Geron Corp. during the second quarter worth approximately $108,000. Finally, GSA Capital Partners LLP boosted its position in Geron Corp. by 25.1% in the second quarter. GSA Capital Partners LLP now owns 170,200 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 34,200 shares during the last quarter. Institutional investors and hedge funds own 38.10% of the company’s stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/geron-corp-gern-given-consensus-recommendation-of-buy-by-brokerages.html
Geron Corp. (NASDAQ:GERN) traded up 2.88% during trading on Tuesday, reaching $2.14. The company’s stock had a trading volume of 885,033 shares. The firm’s 50-day moving average is $2.36 and its 200-day moving average is $2.71. The stock has a market cap of $340.56 million, a P/E ratio of 267.50 and a beta of 2.63. Geron Corp. has a 52-week low of $1.84 and a 52-week high of $5.30.
Geron Corp. (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. The company earned $0.21 million during the quarter, compared to analysts’ expectations of $0.38 million. Geron Corp. had a return on equity of 0.89% and a net margin of 3.39%. Geron Corp.’s revenue for the quarter was down 15.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.06) EPS. Equities research analysts forecast that Geron Corp. will post ($0.23) EPS for the current year.
About Geron Corp.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.
Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with MarketBeat.com's FREE daily email newsletter.